Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ICAD Inc ICAD

Healthcare Medical Devices
iCAD, Inc. provides artificial intelligence-powered cancer detection. Its ProFound Breast Health Suite enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Cancer Detection segment solutions include advanced artificial intelligence and image analysis workflow solutions that enable healthcare professionals to better serve patients by... see more

Recent & Breaking News (NDAQ:ICAD)

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating iCAD, Inc. for Potential Breach of Fiduciary Duty Claims

ACCESSWIRE IA July 2, 2020

iCAD Added to Russell 2000® Index

GlobeNewswire June 29, 2020

iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19

GlobeNewswire June 1, 2020

iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

GlobeNewswire May 13, 2020

iCAD Reports First Quarter 2020 Financial Results

GlobeNewswire May 11, 2020

iCAD to Report First Quarter 2020 Financial Results on Monday, May 11

GlobeNewswire May 5, 2020

iCAD Announces Pricing of $12.5 Million Registered Direct Offering

GlobeNewswire April 23, 2020

iCAD Partners with the TME Breast Care Network to Host Virtual Event: Breast Care Roundtable in the Age of COVID-19

GlobeNewswire April 13, 2020

iCAD Announces New Credit Facility with Bridge Bank, Increasing Operational Flexibility

GlobeNewswire March 31, 2020

iCAD Launches New Initiatives Leveraging Unique Capabilities of its Robust Product Portfolio to Reduce Health Care System Pressures During the COVID-19 Pandemic

GlobeNewswire March 23, 2020

iCAD Reports Fourth Quarter and Full-Year 2019 Financial Results

GlobeNewswire February 27, 2020

UPDATE -- iCAD to Report Fourth Quarter 2019 Financial Results on Thursday, February 27

GlobeNewswire February 13, 2020

iCAD to Report Fourth Quarter 2019 Financial Results on Thursday, February 27, 2020

GlobeNewswire February 13, 2020

iCAD to Participate in the 40th Annual Cowen Healthcare Conference

GlobeNewswire February 12, 2020

First Brain Tumor Treated with Xoft IORT in the United States

GlobeNewswire February 11, 2020

iCAD Showcases Technology for Cancer "Discovery to Recovery" including ProFound AI Platform and Xoft System at Arab Health 2020 in Dubai

GlobeNewswire January 27, 2020

iCAD Appoints Nathaniel Dalton to its Board of Directors

GlobeNewswire January 13, 2020

iCAD's ProFound AI Joins Nuance AI Marketplace for Diagnostic Imaging

GlobeNewswire December 4, 2019

iCAD to Showcase Leading Breast Health Solutions Suite Including Expanded ProFound AI(TM) Platform at RSNA Annual Meeting

GlobeNewswire December 2, 2019

iCAD to Participate at the Piper Healthcare Conference

GlobeNewswire November 26, 2019